383 related articles for article (PubMed ID: 31105909)
1. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O
J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909
[No Abstract] [Full Text] [Related]
2. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
[No Abstract] [Full Text] [Related]
3. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
[TBL] [Abstract][Full Text] [Related]
4. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia.
Wang T; Scuffham P; Byrnes J; Downes M
J Neurol; 2022 Dec; 269(12):6544-6554. PubMed ID: 35980467
[TBL] [Abstract][Full Text] [Related]
7. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
Al-Zaidy SA; Kolb SJ; Lowes L; Alfano LN; Shell R; Church KR; Nagendran S; Sproule DM; Feltner DE; Wells C; Ogrinc F; Menier M; L'Italien J; Arnold WD; Kissel JT; Kaspar BK; Mendell JR
J Neuromuscul Dis; 2019; 6(3):307-317. PubMed ID: 31381526
[TBL] [Abstract][Full Text] [Related]
8. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.
Thokala P; Stevenson M; Kumar VM; Ren S; Ellis AG; Chapman RH
Cost Eff Resour Alloc; 2020; 18():41. PubMed ID: 33041673
[TBL] [Abstract][Full Text] [Related]
10. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis.
Shih ST; Farrar MA; Wiley V; Chambers G
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343
[TBL] [Abstract][Full Text] [Related]
11. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
Al-Zaidy SA; Mendell JR
Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
[TBL] [Abstract][Full Text] [Related]
12. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
Bitetti I; Lanzara V; Margiotta G; Varone A
Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
[TBL] [Abstract][Full Text] [Related]
13. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma).
Ogbonmide T; Rathore R; Rangrej SB; Hutchinson S; Lewis M; Ojilere S; Carvalho V; Kelly I
Cureus; 2023 Mar; 15(3):e36197. PubMed ID: 37065340
[TBL] [Abstract][Full Text] [Related]
15. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
16. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
[TBL] [Abstract][Full Text] [Related]
17. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.
Al-Zaidy S; Pickard AS; Kotha K; Alfano LN; Lowes L; Paul G; Church K; Lehman K; Sproule DM; Dabbous O; Maru B; Berry K; Arnold WD; Kissel JT; Mendell JR; Shell R
Pediatr Pulmonol; 2019 Feb; 54(2):179-185. PubMed ID: 30548438
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
19. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy.
Lee S; Lee YJ; Kong J; Ryu HW; Shim YK; Han JY; Woo H; Kim SY; Cho A; Lim BC; Chae JH
Brain Dev; 2022 Apr; 44(4):287-293. PubMed ID: 35033405
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]